Mazdutide for Fat Loss
GLP-1 / glucagon dual agonist (Innovent / Eli Lilly) submitted in China for obesity 2024.
Why Mazdutide for fat loss?
Mazdutide (IBI362, originally LY3305677) is a weekly GLP-1R/GCGR dual agonist licensed by Innovent from Eli Lilly for greater China. Phase 3 GLORY-1 (2024) reported ~14-15% mean weight loss at 48 weeks at the 6 mg dose. NMPA submission filed in China for obesity in 2024.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Mazdutide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Weight loss with energy expenditure boost
- Hepatic fat reduction
Reference dosing by bodyweight
Anchored to the most-cited research dose (3000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1870–2530 mcg |
| 60–75 kg / 132–165 lb | 2295–3105 mcg |
| 75–90 kg / 165–198 lb | 2805–3795 mcg |
| 90–105 kg / 198–231 lb | 3315–4485 mcg |
| >105 kg / >231 lb | 3825–5175 mcg |
Side effects to weigh against fat loss benefit
- GI events
- Decreased appetite
- Injection-site reactions
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.